Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 17/20 | 0.91 |
| ▸ | BCR | P11274 | 17/20 | 0.91 |
| ▸ | KIT | P10721 | 7/20 | 0.91 |
| ▸ | LYN | P07948 | 4/20 | 0.91 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.91 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.91 |
| ▸ | EGFR | P00533 | 2/20 | 0.91 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.91 |
| ▸ | LCK | P06239 | 2/20 | 0.91 |
| ▸ | FYN | P06241 | 2/20 | 0.91 |
| ▸ | CSF1R | P07333 | 2/20 | 0.91 |
| ▸ | FGR | P09769 | 2/20 | 0.91 |
| ▸ | SRC | P12931 | 2/20 | 0.91 |
| ▸ | BRAF | P15056 | 2/20 | 0.91 |
| ▸ | NQO2 | P16083 | 2/20 | 0.91 |
| ▸ | EPHA8 | P29322 | 2/20 | 0.91 |
| ▸ | ABL2 | P42684 | 2/20 | 0.91 |
| ▸ | FRK | P42685 | 2/20 | 0.91 |
| ▸ | BLK | P51451 | 2/20 | 0.91 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.91 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Masitinib SCHEMBL29355443 | 0.95 | ABL1 (1.00) | ABL1BCRKITLYNPDGFRA | |
| Masitinib SCHEMBL717239 | 0.95 | ABL1 (1.00) | ABL1BCRKITLYNPDGFRA | |
| Masitinib SCHEMBL29353195 | 0.95 | ABL1 (1.00) | ABL1BCRKITLYNPDGFRA | |
| SCHEMBL5971854 | 0.93 | ABL1 (0.80) | ABL1BCRKITLYNPDGFRA | |
| Masitinib SCHEMBL1096348 | 0.93 | ABL1 (0.94) | ABL1BCRKITLYNPDGFRA | |
| Masitinib SCHEMBL2297143 | 0.93 | ABL1 (0.94) | ABL1BCRKITLYNPDGFRA | |
| Masitinib SCHEMBL30024483 | 0.93 | ABL1 (0.94) | ABL1BCRKITLYNPDGFRA | |
| SCHEMBL14566854 | 0.92 | ABL1 (0.77) | ABL1BCRKITLYNPDGFRA | |
| SCHEMBL14286281 | 0.90 | ABL1 (0.84) | ABL1BCRKITLYNPDGFRA | |
| SCHEMBL16085058 | 0.89 | ABL1 (0.89) | ABL1BCRKITLYNPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207572-A1 | Use of Dual C-Kit/Fgfr3 Inhibitors for Treating Multiple Myeloma | AB SCIENCE | 2008-08-28 | — | — | US | claimed |
| EP-2117531-B1 | COMBINATION TREATMENT OF SOLID CANCERS WITH ANTIMETABOLITES AND TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2016-11-02 | — | — | EP | disclosed |
| EP-2117531-B1 | COMBINATION TREATMENT OF SOLID CANCERS WITH ANTIMETABOLITES AND TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2016-11-02 | — | — | EP | disclosed |
| US-8227470-B2 | Combination treatment of solid cancers with antimetabolites and tyrosine kinase inhibitors | AB SCIENCE (FR) | 2012-07-24 | — | — | US | disclosed |
| US-8227470-B2 | Combination treatment of solid cancers with antimetabolites and tyrosine kinase inhibitors | AB SCIENCE (FR) | 2012-07-24 | — | — | US | disclosed |
| US-8227470-B2 | Combination treatment of solid cancers with antimetabolites and tyrosine kinase inhibitors | AB SCIENCE (FR) | 2012-07-24 | — | — | US | disclosed |
| US-20100093750-A1 | COMBINATION TREATMENT OF SOLID CANCERS WITH ANTIMETABOLITES AND TYROSINE KINASE INHIBITORS | AB SCIENCE | 2010-04-15 | — | — | US | disclosed |
| US-20100093750-A1 | COMBINATION TREATMENT OF SOLID CANCERS WITH ANTIMETABOLITES AND TYROSINE KINASE INHIBITORS | AB SCIENCE | 2010-04-15 | — | — | US | disclosed |
| US-20100093750-A1 | COMBINATION TREATMENT OF SOLID CANCERS WITH ANTIMETABOLITES AND TYROSINE KINASE INHIBITORS | AB SCIENCE | 2010-04-15 | — | — | US | disclosed |
| US-20080207572-A1 | Use of Dual C-Kit/Fgfr3 Inhibitors for Treating Multiple Myeloma | AB SCIENCE | 2008-08-28 | — | — | US | disclosed |
| US-20080207572-A1 | Use of Dual C-Kit/Fgfr3 Inhibitors for Treating Multiple Myeloma | AB SCIENCE | 2008-08-28 | — | — | US | disclosed |
| US-20080207572-A1 | Use of Dual C-Kit/Fgfr3 Inhibitors for Treating Multiple Myeloma | AB SCIENCE | 2008-08-28 | — | — | US | disclosed |
| WO-2008084103-A1 | COMBINATION TREATMENT OF SOLID CANCERS WITH ANTIMETABOLITES AND TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207572-A1 | Use of Dual C-Kit/Fgfr3 Inhibitors for Treating Multiple Myeloma | KIT, FGFR3, AURKC | ABL1 23/4885BCR 15/4885KIT 1/4885 |
| US-20100093750-A1 | COMBINATION TREATMENT OF SOLID CANCERS WITH ANTIMETABOLITES AND TYROSINE KINASE INHIBITORS | ERBB2, ERBB3, ERBB4 | ABL1 14/4885BCR 214/4885KIT 2283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.